AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$TVTX

Cline Christopher R. sold $43K of TVTX

Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold 642 shares of Travere Therapeutics, Inc. (TVTX) at $66.37 on 2026-09-02.

Original reporting
SEC EDGAR · Cline Christopher R.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TVTX
Bearish
high confidence
Mentioned
$TVTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TVTXBearishLow
01

Why it matters

The CFO's modest sale is unlikely to affect investor sentiment significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Insider may be diversifying; the remaining stake remains sizable, mitigating concern.

Relevance 3/10Novelty 4/10Timing: filed Sep 3 2026

Background

Form 4 filing discloses insider transactions to the SEC; investors monitor these for potential signals.

Company-level read

Ticker impact

$TVTXBearishHigh confidence
Context

CFO Christopher Cline sold 642 shares of Travere Therapeutics for $42,609, reducing his stake to 118,016 shares.

Expected impact

Small downward bias, likely <1% impact.

Evidence & confidence

The sale size is modest relative to float and market cap; CFO insider sales are watched but this amount is not material.

Market effects

Sector

No broader sector impact; biotech sector unchanged.

Regional

US market only; no regional ripple.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a signal of company weakness.

Key entities

  • Company
    Travere Therapeutics, Inc.

    US-listed biotech company (ticker TVTX).

  • Individual
    Christopher R. Cline

    Chief Financial Officer of Travere Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TVTX insider trading history →

Related articles

AUG 4
$TVTXMed

Travere Therapeutics, Inc. (TVTX): Results of Operations and Financial Condition

Travere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during

SEC EDGAR 8-K6 min
JUL 8
$TVTXMedAI 8/10

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib – IT Business Net

Everest Medicines (HKEX 1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ TVTX) for civorebrutinib (EVER001) in the US and global markets excluding Greater China and parts of East and Southeast Asia. Everest will receive a $112.5m upfront payment, plus up to about $1.03b milestone payments and tiered royalties on sales.

itbusinessnet.com4 min
JUL 8
$TVTXMedAI 8/10

Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines (HKEX:1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ:TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East/Southeast Asia. Everest will receive $112.5m upfront and up to ~$1.03b in milestone payments, plus tiered royalties on sales.

finanznachrichten.de3 min
JUL 7
$TVTXMed

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines (HKEX:1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ:TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East/Southeast Asia. Everest will receive $112.5M upfront, plus up to ~$1.03B in milestone payments and tiered royalties on sales.

manilatimes.net4 min